Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07641049CT.gov Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT06193486CT.gov Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | — | Recruiting | — | — | — |
NCT06228404CT.gov Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | — | Active Not Recruiting | — | — | — |
NCT04227275CT.gov A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03873805CT.gov PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03692663CT.gov Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Beijing Biotech | P1 | CC · 42 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Prednisone | Mayo Clinic | P4 | BB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Sipuleucel-T | Yale University | P2 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →